SECOND OPINION: PHRMA REDUXES DEBUNKED BLAME GAME RHETORIC IN NEW AD CAMPAIGN

Big Pharma Trots Out Tired, Dishonest Arguments Designed to Evade Accountability, Keep Prices High As lawmakers in Congress continue to weigh market-based solutions to lower prescription drug

06-17-2022 Read More

THEY SAID IT! ANTITRUST EXPERTS AND OFFICIALS SHINE A LIGHT ON BIG PHARMA’S ANTI-COMPETITIVE PLAYBOOK

Federal Trade Commission Workshop Highlights How Brand Name Drug Companies Game the System to Keep Prices High — Demonstrating the Urgency for Congress to Act This week

06-16-2022 Read More

DOSE OF REALITY: BIG PHARMA TARGETS MERGERS AND ACQUISITIONS TO KEEP PRICES HIGH, EXTEND MONOPOLIES AND BOOST PROFITS

FTC Workshop Can Highlight How Brand Name Drug Companies Employ Anti-Competitive Tactics to Game the System — Driven by Focus on Profits Over People This week

06-13-2022 Read More

BIG PHARMA WATCH: PHARMACEUTICAL COMPANIES HIKED LAUNCH PRICES BY 20 PERCENT EVERY YEAR FOR 14 YEARS

Nearly Half of All New Brand Name Drugs Cost More Than $150,000 Per Year In case you missed it, a new academic study published in The Journal of the American Medical Association (JAMA) from

06-9-2022 Read More

ICYMI: CBO FINDS HOLDING BIG PHARMA ACCOUNTABLE FOR ANTI-COMPETITIVE TACTICS WOULD SAVE BILLIONS OF DOLLARS

Scoring Shows Solutions to Crack Down on Branded Drug Companies’ Anti-Competitive Tactics Would Save Consumers Billions and Bring More Affordable Alternatives to Market In case you missed it, on

06-8-2022 Read More

BIG PHARMA WATCH: REPORTS SHOW BIG PHARMA HAD ANOTHER BANNER YEAR IN 2021

Brand Name Drug Companies Posted Massive Profit Growth and Invested Heavily in Share Buybacks and Dividends Two recent reports from Evaluate Vantage and Endpoints News detail the banner year Big

06-3-2022 Read More

BIG PHARMA WATCH: STUDY FINDS BIG PHARMA TARGETS MOST PROFITABLE DRUGS FOR NEW FORMULATIONS TO BLOCK COMPETITION

Brand Name Drug Companies Four Times as Likely to Reformulate Blockbuster Products to Extend Market Exclusivity In case you missed it, a recent study published in JAMA Health Forum examines Big

05-25-2022 Read More

ICYMI: ANALYSIS REVEALS IMPACT OF BIG PHARMA’S ANTI-COMPETITIVE PRACTICES AROUND INHALERS

Brand Name Drug Companies Prevent Competition from More Affordable Alternatives by Gaming the Patent System and Deploying Tactics Like Product Hopping In case you missed it

05-18-2022 Read More

BIG PHARMA WATCH: NEW ANALYSIS FINDS BIG PHARMA REAPS BIG MULTIPLES FROM MEDICARE SPENDING ON TOP DRUGS

Part D Spending on 10 Most Popular Medications Over Five Years Averages Five Times What Drug Companies Claim to Invest in R&D In case you missed it

05-13-2022 Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.